Page last updated: 2024-11-05

thalidomide and Angiofollicular Lymph Hyperplasia

thalidomide has been researched along with Angiofollicular Lymph Hyperplasia in 22 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

ExcerptRelevanceReference
"We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease."8.88[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012)
"Considering the involvement of IL-6 in Castleman's disease we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome."5.32Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. ( Canelles, MF; Menegato, MA; Pizzolitto, S; Tonutti, E, 2004)
"We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease."4.88[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012)
"The diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyradiculoneuropathy and clonal PCD, and at least one of the minor criteria."2.61POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. ( Dispenzieri, A, 2019)
"Castlemans disease is the term for reactive lymphocytary and plasmocytary proliferation which occurs in the unicentric (localized) form, usually without systemic symptoms, or in the generalized/multicentric form, typically with systemic symptoms (www."2.53[Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature]. ( Adam, Z; Čermáková, Z; Hanke, I; Koukalová, R; Král, Z; Krejčí, M; Křen, L; Mayer, J; Michalková, E; Penka, I; Petrášová, H; Pour, L; Pourová, E; Řehák, Z; Sandecká, V; Ševčíková, S; Sokol, F; Szturz, P; Volfová, P, 2016)
"POEMS syndrome is a clonal plasma cell disease characterized by polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes."2.49New advances in the diagnosis and treatment of POEMS syndrome. ( Li, J; Zhou, DB, 2013)
"Systematic search for monoclonal gammopathy by immunofixation and serum free light chains is very useful for the management of progressive peripheral neuropathies of unknown origin."2.47[New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome]. ( Adams, D; Bourhis, JH; Lacroix, C; Lozeron, P; Ribrag, V; Theaudin, M, 2011)
"Castlemans disease (also called angiofollicular lymph node hyperplasia) can take two forms with different prognosis: the localized form can usually be treated by a surgical intervention and has therefore a favourable prognosis."1.39[PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview]. ( Adam, Z; Cervinková, I; Hanke, I; Koukalová, R; Král, Z; Krejčí, M; Křen, L; Mayer, J; Penka, I; Pour, L; Rehák, Z; Storková, T; Svoboda, T; Szturz, P, 2013)
"Castleman disease is a rare lymphoproliferative disorder."1.35Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris. ( Gonda, A; Illes, A; Miltenyi, Z; Remenyik, E; Tar, I; Toth, J, 2009)
"Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology."1.32Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. ( Lee, FC; Merchant, SH, 2003)
"Considering the involvement of IL-6 in Castleman's disease we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome."1.32Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. ( Canelles, MF; Menegato, MA; Pizzolitto, S; Tonutti, E, 2004)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (31.82)29.6817
2010's14 (63.64)24.3611
2020's1 (4.55)2.80

Authors

AuthorsStudies
Lomas, OC1
Streetly, M1
Pratt, G1
Cavet, J1
Royston, D1
Schey, S2
Ramasamy, K2
Zhou, X1
Wei, J1
Lou, Y1
Xu, G1
Yang, M1
Liu, H1
Mao, L1
Tong, H1
Jin, J1
van Rhee, F1
Stone, K1
Dispenzieri, A1
Adam, Z4
Szturz, P4
Křen, L2
Krejčí, M4
Pour, L4
Svoboda, T1
Hanke, I2
Penka, I2
Koukalová, R4
Rehák, Z4
Cervinková, I1
Storková, T1
Král, Z3
Mayer, J4
Lin, Q1
Fang, B1
Huang, H1
Yu, F1
Chai, X1
Zhang, Y1
Zhou, J1
Xia, Q1
Li, Y1
Song, Y1
Michalková, E1
Pourová, E1
Volfová, P1
Sandecká, V1
Čermáková, Z1
Sokol, F1
Petrášová, H1
Ševčíková, S1
Stary, G1
Kohrgruber, N1
Herneth, AM1
Gaiger, A1
Stingl, G1
Rieger, A1
Miltenyi, Z1
Toth, J1
Gonda, A1
Tar, I1
Remenyik, E1
Illes, A1
Adams, D1
Lozeron, P1
Theaudin, M1
Ribrag, V1
Bourhis, JH1
Lacroix, C1
Zhao, X1
Shi, R1
Jin, X1
Zheng, J1
Wang, X1
Ye, S1
Xiong, C1
Gao, J1
Xiao, C1
Xing, X1
Chovancová, J1
Stehlíková, O1
Klabusay, M1
Zahradová, L2
Hájek, R2
Briani, C1
Manara, R1
Lessi, F1
Citton, V1
Zambello, R1
Adami, F1
Gandhi, S1
Tenant-Flowers, M1
Ceesay, M1
Corderoy, S1
Marcus, R1
Nebeský, T1
Li, J1
Zhou, DB1
Lee, FC2
Merchant, SH1
Jung, CP1
Emmerich, B1
Goebel, FD1
Bogner, JR1
Menegato, MA1
Canelles, MF1
Tonutti, E1
Pizzolitto, S1
Starkey, CR1
Joste, NE1
Kim, SY1
Lee, SA1
Ryoo, HM1
Lee, KH1
Hyun, MS1
Bae, SH1

Reviews

5 reviews available for thalidomide and Angiofollicular Lymph Hyperplasia

ArticleYear
POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.
    American journal of hematology, 2019, Volume: 94, Issue:7

    Topics: Adrenal Cortex Hormones; Allografts; Bortezomib; Castleman Disease; Diagnosis, Differential; Humans;

2019
[Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature].
    Vnitrni lekarstvi, 2016, Volume: 62, Issue:4

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Castleman Disease; Drug Therapy, Combination;

2016
[New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome].
    Revue neurologique, 2011, Volume: 167, Issue:1

    Topics: Amyloid; Amyloid Neuropathies; Biomarkers; Biopsy; Castleman Disease; Combined Modality Therapy; Dru

2011
[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].
    Vnitrni lekarstvi, 2012, Volume: 58, Issue:11

    Topics: Aged; Castleman Disease; Erdheim-Chester Disease; Female; Histiocytosis, Langerhans-Cell; Humans; Le

2012
New advances in the diagnosis and treatment of POEMS syndrome.
    British journal of haematology, 2013, Volume: 161, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromo

2013

Other Studies

17 other studies available for thalidomide and Angiofollicular Lymph Hyperplasia

ArticleYear
The management of Castleman disease.
    British journal of haematology, 2021, Volume: 195, Issue:3

    Topics: Adrenal Cortex Hormones; Anti-Retroviral Agents; Antibodies, Monoclonal; Antineoplastic Combined Che

2021
Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.
    Frontiers of medicine, 2017, Volume: 11, Issue:2

    Topics: Adult; Castleman Disease; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans

2017
Storming the Castle with TCP.
    Blood, 2019, 04-18, Volume: 133, Issue:16

    Topics: Castleman Disease; Cyclophosphamide; Humans; Prednisone; Thalidomide; Thyroid Neoplasms

2019
[PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview].
    Vnitrni lekarstvi, 2013, Volume: 59, Issue:4

    Topics: Castleman Disease; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Huma

2013
Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease.
    Blood cancer journal, 2015, Mar-20, Volume: 5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Castleman Dis

2015
Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Castleman Disease; HIV Infections; H

2008
Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris.
    Pathology oncology research : POR, 2009, Volume: 15, Issue:3

    Topics: Adrenal Cortex Hormones; Castleman Disease; Cyclosporine; Female; Humans; Immunomodulation; Immunosu

2009
Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: report of three cases.
    Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:2

    Topics: Adult; Biopsy, Needle; Castleman Disease; Diagnosis, Differential; Drug Therapy, Combination; Female

2011
Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:10

    Topics: Adult; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Castleman Disease; Drug Therapy, Combinat

2011
Lenalidomide: a new treatment option for Castleman disease.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Castleman Disease; Humans; Le

2012
Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy.
    American journal of hematology, 2012, Volume: 87, Issue:5

    Topics: Aged; Castleman Disease; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans;

2012
Rituximab and thalidomide combination therapy for Castleman disease.
    British journal of haematology, 2012, Volume: 158, Issue:3

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Castleman Disease; Drug Therapy, Combination; Female;

2012
Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide.
    American journal of hematology, 2003, Volume: 73, Issue:1

    Topics: Adult; Anemia; Antibodies, Viral; Axilla; Biopsy; Castleman Disease; Cytokines; Female; Herpesvirus

2003
Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide.
    American journal of hematology, 2004, Volume: 75, Issue:3

    Topics: Adult; Angiogenesis Inhibitors; Castleman Disease; HIV Infections; Humans; Immunosuppressive Agents;

2004
Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease.
    Clinical nephrology, 2004, Volume: 61, Issue:5

    Topics: Aged; Biopsy; Castleman Disease; Female; Glomerulonephritis, Membranoproliferative; Humans; Immunosu

2004
Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide.
    American journal of hematology, 2006, Volume: 81, Issue:4

    Topics: Angiogenesis Inhibitors; Biopsy; Castleman Disease; Female; Humans; Lymph Nodes; Remission Induction

2006
Thalidomide for POEMS syndrome.
    Annals of hematology, 2006, Volume: 85, Issue:8

    Topics: Adult; Anti-Inflammatory Agents; Castleman Disease; Dexamethasone; Female; Humans; Immunosuppressive

2006